Trombopag 25 ( eltrombopag 25 mg )

Eltrombopag brands in india is Trombopag 25 mg, is a medication that activates the thrombopoietin receptor and is prescribed for various medical conditions. It is approved for use in adult and pediatric patients aged one year and older who have persistent or chronic immune thrombocytopenia (ITP) and have not responded well to other treatments such as corticosteroids, immunoglobulins, or splenectomy. However, it should only be used in patients with ITP who have an increased risk of bleeding due to their degree of thrombocytopenia and clinical condition.

In addition, Eltrombopag is indicated for the treatment of thrombocytopenia in patients with chronic hepatitis C who need to start or maintain interferon-based therapy, but are unable to do so due to their degree of thrombocytopenia. Nevertheless, it should only be used in patients whose thrombocytopenia limits their ability to initiate or continue interferon-based therapy.

Furthermore, Eltrombopag can be used along with standard immunosuppressive therapy as a first-line treatment for severe aplastic anemia in adult and pediatric patients aged two years and older. It can also be used for patients with severe aplastic anemia who have not responded well to immunosuppressive therapy.

However, Eltrombopag is not recommended for the treatment of patients with myelodysplastic syndrome (MDS). Additionally, its safety and effectiveness have not been established when used in combination with direct-acting antiviral agents for the treatment of chronic hepatitis C infection without interferon.

Eltrombopag 25 mg price in India

Eltrombopag manufacturer in India is Trombopag 25 mg. Eltrombopag price in india in India is only 259 USD per boxes, which is only 4% of eltrombopag price in India.

Eltrombopa Dosing

When taking Eltrombopag, it is recommended to either take it on an empty stomach or with a low-calcium meal (≤50 mg). It is also advised to take Eltrombopag at least 2 hours before or 4 hours after any medications or products that contain polyvalent cations, such as antacids, calcium-rich foods, and mineral supplements.

For persistent or chronic ITP, the recommended initial dose of Eltrombopag is 50 mg once daily for most adult and pediatric patients aged 6 years and older. For pediatric patients aged 1 to 5 years, the recommended initial dose is 25 mg once daily. Dose reductions are required for patients with hepatic impairment and some patients of East-/Southeast-Asian ancestry. The dose should be adjusted to maintain a platelet count of ≥50 x 109 /L, and the daily dose should not exceed 75 mg.

For chronic hepatitis C-associated thrombocytopenia, the recommended initial dose of Eltrombopag is 25 mg once daily for all patients. The dose should be adjusted to achieve the target platelet count required to initiate antiviral therapy. The daily dose should not exceed 100 mg.

In first-line severe aplastic anemia, Eltrombopag should be initiated once daily at 2.5 mg/kg for pediatric patients aged 2 to 5 years old, 75 mg for pediatric patients aged 6 to 11 years old, or 150 mg for patients aged 12 years and older, concurrently with standard immunosuppressive therapy. The initial dose should be reduced in patients of East-/Southeast-Asian ancestry. Dosage should be modified for toxicity or elevated platelet counts.

For refractory severe aplastic anemia, the recommended initial dose of Eltrombopag is 50 mg once daily. The initial dose should be reduced in patients with hepatic impairment or patients of East-/Southeast-Asian ancestry. The dose should be adjusted to maintain a platelet count greater than 50 x 109 /L, and the daily dose should not exceed 150 mg.

Eltrombopag olamine side effects

Severe side effects may occur when taking ELTROMBOPAG, including:

• Exacerbation of a pre-cancerous blood condition leading to acute myelogenous leukemia (AML), a type of blood cancer. ELTROMBOPAG is not recommended for individuals with myelodysplastic syndromes (MDS), a pre-cancerous state. If you have MDS and take ELTROMBOPAG, your condition may worsen and potentially result in AML, which can be fatal.

• Elevated platelet counts and an increased risk of blood clots. Treatment with Eltrombopag may increase platelet counts, which can raise the risk of blood clots. The risk of blood clots may also be higher during Eltrombopag therapy in people with normal or low platelet counts. Blood clots can lead to serious complications such as pulmonary embolism, heart attack, or stroke, and may be fatal. Your healthcare provider will monitor your platelet counts and adjust your dose or stop Eltrombopag if your platelet counts become too high. Inform your healthcare provider immediately if you experience leg swelling, pain, or tenderness, which may be signs of a blood clot.

• Chronic liver disease patients may have a higher risk of blood clots in the stomach area. Inform your healthcare provider immediately if you experience stomach area pain, which could be a sign of this type of blood clot.

• Development or worsening of cataracts, which cause clouding of the eye's lens. ELTROMBOPAG has been linked to new or worsened cataracts. Your healthcare provider will perform eye exams before and during your treatment with Eltrombopag. Inform your healthcare provider if there are any changes in your vision while taking Eltrombopag.

Eltrombopag pi

Please consult the "FDA Prescribing Information" for further details on prescribing.